PMID- 29537988 OWN - NLM STAT- MEDLINE DCOM- 20190801 LR - 20190801 IS - 1473-5849 (Electronic) IS - 0955-8810 (Linking) VI - 29 IP - 6 DP - 2018 Sep TI - Effects on brain-derived neurotrophic factor signalling of chronic mild stress, chronic risperidone and acute intracranial dopamine receptor challenges. PG - 537-542 LID - 10.1097/FBP.0000000000000392 [doi] AB - We have previously reported the effects of intracranial injections of dopamine D1, D2 and D3 ligands in animals subjected to the Novel Object Recognition (NOR) test following exposure to chronic mild stress (CMS) and chronic treatment with risperidone (RSP). Here, we present some molecular biological data from the same animals. It was predicted that brain-derived neurotrophic factor (BDNF) signalling in the prefrontal cortex (PFC) would reflect behavioural performance, implying an increase following acute administration of a D2 agonist or a D3 antagonist, blockade of this effect by CMS and its restoration by chronic RSP. In separate cohorts, animals were injected within the PFC or the hippocampus (HPC) with either the D1 agonist SKF-81297, the D2 agonist quinpirole or the D3 antagonist SB-277,011, following exposure to control conditions or CMS and chronic treatment with saline or RSP. Intracranial injections followed an exposure trial in the NOR test, with a retention trial 24 h later. Immediately afterwards, the animals were killed and expression of BDNF and TRKbeta protein, and their respective mRNAs, was measured in PFC and HPC samples. CMS decreased the expression of TRKbeta in both PFC and HPC. Several effects associated with intracranial injection were noted, but they were inconsistent and unrelated to CMS exposure. The effects of CMS on TRKbeta are consistent with a decrease in BDNF signalling, albeit that expression of BDNF itself did not change significantly. There was no evidence for an involvement of the BDNF-TRKbeta system in responses to RSP or dopamine ligands in animals exposed to CMS. However, there was a 24 h delay between the intracranial injection and tissue harvesting, meaning that brief early drug effects could have been missed. FAU - Papp, Mariusz AU - Papp M AD - Department of Pharmacology, Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland. FAU - Gruca, Piotr AU - Gruca P AD - Department of Pharmacology, Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland. FAU - Lason-Tyburkiewicz, Magdalena AU - Lason-Tyburkiewicz M AD - Department of Pharmacology, Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland. FAU - Litwa, Ewa AU - Litwa E AD - Department of Pharmacology, Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland. FAU - Niemczyk, Monika AU - Niemczyk M AD - Department of Pharmacology, Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland. FAU - Tota-Glowczyk, Katarzyna AU - Tota-Glowczyk K AD - Department of Pharmacology, Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland. FAU - Faron-Gorecka, Agata AU - Faron-Gorecka A AD - Department of Pharmacology, Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland. FAU - Kusmider, Maciej AU - Kusmider M AD - Department of Pharmacology, Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland. FAU - Solich, Joanna AU - Solich J AD - Department of Pharmacology, Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland. FAU - Szlachta, Marta AU - Szlachta M AD - Department of Pharmacology, Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland. FAU - Willner, Paul AU - Willner P AD - Department of Psychology, Swansea University, Swansea, UK. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - England TA - Behav Pharmacol JT - Behavioural pharmacology JID - 9013016 RN - 0 (Antipsychotic Agents) RN - 0 (Benzazepines) RN - 0 (Brain-Derived Neurotrophic Factor) RN - 0 (Dopamine Agents) RN - 0 (RNA, Messenger) RN - 0 (Receptors, Dopamine) RN - 20OP60125T (Quinpirole) RN - 71636-61-8 (SK&F 81297) RN - L6UH7ZF8HC (Risperidone) MH - Animals MH - Antipsychotic Agents/*therapeutic use MH - Benzazepines/pharmacology MH - Brain-Derived Neurotrophic Factor/genetics/*metabolism MH - Disease Models, Animal MH - Dopamine Agents/pharmacology MH - Electroencephalography MH - Male MH - Prefrontal Cortex/drug effects/metabolism MH - Quinpirole/pharmacology MH - RNA, Messenger/metabolism MH - Rats MH - Rats, Wistar MH - Receptors, Dopamine/*metabolism MH - Risperidone/*therapeutic use MH - Signal Transduction/*drug effects MH - Stress, Psychological/*drug therapy EDAT- 2018/03/15 06:00 MHDA- 2019/08/02 06:00 CRDT- 2018/03/15 06:00 PHST- 2018/03/15 06:00 [pubmed] PHST- 2019/08/02 06:00 [medline] PHST- 2018/03/15 06:00 [entrez] AID - 10.1097/FBP.0000000000000392 [doi] PST - ppublish SO - Behav Pharmacol. 2018 Sep;29(6):537-542. doi: 10.1097/FBP.0000000000000392.